第63屆美國血液學(xué)會(huì)(ASH)將于2021年12月11-14日在美國亞特蘭大以線上+線下的形式舉行。作為全球首屈一指的血液學(xué)領(lǐng)域的學(xué)術(shù)交流盛會(huì),ASH擁有來自近100個(gè)國家的25000多名會(huì)員,每年都會(huì)公布和發(fā)表世界各國的最新血液學(xué)數(shù)據(jù),匯集該領(lǐng)域最新、最前沿的研究進(jìn)展,重點(diǎn)介紹血液學(xué)最新動(dòng)態(tài)、最熱門話題。
本屆ASH年會(huì),陸道培醫(yī)學(xué)團(tuán)隊(duì)入選了2篇口頭報(bào)告(Oral),8篇墻報(bào)展示(Poster),全面總結(jié)了陸道培醫(yī)學(xué)團(tuán)隊(duì)最新的臨床研究成果。能夠在世界級(jí)學(xué)術(shù)研究舞臺(tái)上發(fā)表專題報(bào)告,代表了全球血液學(xué)領(lǐng)域權(quán)威對陸道培醫(yī)學(xué)團(tuán)隊(duì)的認(rèn)可。
口頭發(fā)言(ORAL)
ORAL 1#
摘要號(hào):473;第一作者:楊君芳,通訊作者:陸佩華
抗CD7 CAR-T細(xì)胞治療復(fù)發(fā)或難治性(R/R)T細(xì)胞急性淋巴細(xì)胞白血病(T-ALL)的高效性和安全性研究
High Effectiveness and Safety of Anti-CD7 CAR T-Cell Therapy in Treating Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)
匯報(bào)時(shí)間:Sunday, December 12, 2021, 1:00 PM
ORAL 2#
摘要號(hào):652;第一作者:楊君芳,通訊作者:陸佩華
一種新型有效的患者或供體來源的CD7靶向CAR-T細(xì)胞治療復(fù)發(fā)或難治性T細(xì)胞淋巴母細(xì)胞淋巴瘤(R/R T-LBL)的研究
A Novel and Successful Patient or Donor-Derived CD7-Targeted CAR T-Cell Therapy for Relapsed or Refractory T-Cell Lymphoblastic Lymphoma (R/R T-LBL)
匯報(bào)時(shí)間:Monday, December 13, 2021, 11:15 AM
墻報(bào)展示(Poster)
POSTER 1#
摘要號(hào):1741;第一作者:張弦,通訊作者:陸佩華
新型CD7靶向CAR-T細(xì)胞治療復(fù)發(fā)或難治性急性混合細(xì)胞白血?。?/span>MPAL)的首個(gè)人體臨床研究
First-In-Human Clinical Study of A Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)
匯報(bào)時(shí)間:Saturday, December 11, 2021, 5:30 PM - 7:30 PM
POSTER 2#
摘要號(hào):3828;第一作者:張弦,通訊作者:陸佩華
CD19 CAR-T細(xì)胞治療TP53 突變/染色體 17p 缺失的難治或復(fù)發(fā)性B細(xì)胞急性淋巴細(xì)胞白血病 (B-ALL) 療效相關(guān)的因素分析
Factors Associated with Outcomes Among Refractory/Relapsed TP53-Mutated/Chromosome 17p Deletion Acute B-Cell Lymphoblastic Leukemia (B-ALL) Patients Treated with CD19-Targeted Chimeric Antigen Receptor (CAR)-T Therapy
匯報(bào)時(shí)間:Monday, December 13, 2021, 6:00 PM-8:00 PM
POSTER 3#
摘要號(hào):2820;第一作者:張弦,通訊作者:陸佩華
CD7CAR-T與 CD19 CAR-T 細(xì)胞治療急性白血病的擴(kuò)增演變比較
Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia
匯報(bào)時(shí)間:Sunday, December 12, 2021, 6:00 PM-8:00 PM
POSTER4#
摘要號(hào):3848;第一作者:曹星玉,通訊作者:陸佩華
一種新型 CMV 特異性 TCR-T 細(xì)胞療法對異基因造血干細(xì)胞移植后難治性 CMV 感染的有效性和安全性研究
A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation
匯報(bào)時(shí)間:Monday, December 13, 2021, 6:00 PM-8:00 PM
POSTER5#
摘要號(hào):1696;第一作者:劉瑩(森朗公司),通訊作者:陸佩華
通過自然選擇無需基因編輯制備的CD7 CAR-T 細(xì)胞可作為治療T 細(xì)胞惡性腫瘤的潛在優(yōu)質(zhì)療法
Naturally Selected Anti-CD7 CAR-T Cells without Additional Genetic Manipulations As a Potentially Superior Therapy for T-Cell Malignancies
匯報(bào)時(shí)間:Saturday, December 11, 2021, 5:30 PM-7:30 PM
POSTER6#
摘要號(hào):1312;第一作者:曹泮翔,通訊作者:劉紅星
基于轉(zhuǎn)錄組分類模型和共表達(dá)網(wǎng)絡(luò)分析鑒定B-ALL中新的CXCR4alt亞型和Blnk基因剪接變異
Transcriptome Based Classification Model and Co-Expression Networks Analysis Identify CXCR4alt Subtype and Blnkaf in B-Cell Precursor Acute Lymphoblastic Leukemia
匯報(bào)時(shí)間:Saturday, December 11, 2021, 5:30 PM-7:30 PM
POSTER7#
摘要號(hào):2243;第一作者:陳佳琦,通訊作者:劉紅星
急性早幼粒細(xì)胞白血病患者復(fù)發(fā)和PML-RARA融合基因耐藥突變分析
Relapse Analysis and Resistance Mutations of PML-RARA Fusion Gene in Acute Promyelocytic Leukemia Patients Treated with All-trans Retinoic Acid and Arsenic
匯報(bào)時(shí)間:Sunday, December 12, 2021, 6:00 PM-8:00 PM
POSTER8#
摘要號(hào):2367;第一作者:周曉蘇,通訊作者:劉紅星
AML中DNTT異常表達(dá)、TdT活化促進(jìn)的基因長度突變、及其與含ATG預(yù)處理方案的移植預(yù)后的相關(guān)性
Aberrant DNTT Expression, TdT-aided Gene Length Mutations, and Prognosis Relevance in ATG Based Regimen allo-HSCT in Acute Myeloid Leukemia
匯報(bào)時(shí)間:Sunday, December 12, 2021, 6:00 PM-8:00 PM
POSTER9#
摘要號(hào):2387;第一作者:陳雪,通訊作者:劉紅星
TCF3-HLF陽性B-ALL患者的臨床和分子特征-單中心24例患者分析
Clinical and Molecular Characteristics of TCF3-HLF Gene Fusion-positive B-cell Precursor Acute Lymphoblastic Leukemia: a Series of 24 Cases From a Large Cohort of Leukemia Patients
匯報(bào)時(shí)間:Sunday, December 12, 2021, 6:00 PM-8:00 PM